Pyxis Oncology (PYXS) Other Working Capital Changes (2020 - 2025)
Pyxis Oncology (PYXS) posted quarterly Other Working Capital Changes of $1.1 million for Q4 2025, up 187.1% year-over-year from $397423.6 in Q4 2024, and up 202.98% quarter-over-quarter from -$1.1 million in Q3 2025.
Pyxis Oncology (PYXS) Other Working Capital Changes (2020 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has reported Other Working Capital Changes for 6 consecutive years, with $1.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Working Capital Changes rose 187.1% year-over-year to $1.1 million; the TTM figure through Dec 2025 stood at $71000.0 (up 105.77% YoY), while the FY2025 annual figure was $71000.0, up 105.77% from the prior year.
- Other Working Capital Changes grew to $1.1 million in Q4 2025 per PYXS's latest filing, from -$1.1 million in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $3.0 million in Q4 2022 and bottomed at -$2.0 million in Q2 2024.
- Historically, Other Working Capital Changes has averaged $161750.0 across 5 years, with a median of $151500.0 in 2021.
- Annual changes were most pronounced in 2022 — Other Working Capital Changes jumped 2406.25% — and 2024, when it sank 675.51%.
- Pyxis Oncology's Other Working Capital Changes stood at -$160000.0 in 2021, then surged by 2406.25% to $3.7 million in 2022, then plunged by 107.78% to -$287000.0 in 2023, then sank by 356.45% to -$1.3 million in 2024, then soared by 187.1% to $1.1 million in 2025.
- Business Quant data shows PYXS's Other Working Capital Changes at $1.1 million in Q4 2025, -$1.1 million in Q3 2025, and $376000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Pyxis Oncology | 199.01 Mn | 166.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.57 Mn |
| Dec 31, 2025 | -1.57 Mn |
| Dec 31, 2025 | -1.57 Mn |
| Sep 30, 2025 | -1.20 Mn |
| Sep 30, 2025 | -1.20 Mn |
| Sep 30, 2025 | -1.20 Mn |
| Jun 30, 2025 | 1.57 Mn |
| Jun 30, 2025 | 1.57 Mn |
| Jun 30, 2025 | 1.57 Mn |
| Mar 31, 2025 | 930,000.00 |
| Mar 31, 2025 | 930,000.00 |
| Mar 31, 2025 | 930,000.00 |
| Dec 31, 2024 | 1.46 Mn |
| Dec 31, 2024 | 1.46 Mn |
| Dec 31, 2024 | 1.46 Mn |
| Sep 30, 2024 | -1.26 Mn |
| Sep 30, 2024 | -1.26 Mn |
| Sep 30, 2024 | -1.26 Mn |
| Jun 30, 2024 | -2.04 Mn |
| Jun 30, 2024 | -2.04 Mn |